Revvity (RVTY) Expected to Announce Quarterly Earnings on Monday

Revvity (NYSE:RVTY) is expected to announce its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of $1.55 per share and revenue of $759.8050 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:00 AM ET.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Monday, October 27th. The company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.04. The business had revenue of $698.95 million during the quarter, compared to analyst estimates of $699.75 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The company’s revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.28 earnings per share. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Price Performance

NYSE:RVTY opened at $116.64 on Monday. The company has a quick ratio of 1.44, a current ratio of 1.75 and a debt-to-equity ratio of 0.36. The business’s 50-day moving average price is $102.18 and its 200 day moving average price is $94.99. Revvity has a 52-week low of $81.36 and a 52-week high of $128.29. The firm has a market cap of $13.22 billion, a P/E ratio of 58.61, a PEG ratio of 3.56 and a beta of 1.05.

Revvity declared that its board has authorized a stock buyback plan on Monday, October 27th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to buy up to 8.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Revvity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its position in shares of Revvity by 22.3% in the third quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock worth $191,034,000 after buying an additional 397,160 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Revvity by 15.7% in the third quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock worth $223,816,000 after buying an additional 346,313 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Revvity in the 2nd quarter worth $30,106,000. Bank of America Corp DE grew its position in shares of Revvity by 40.7% in the third quarter. Bank of America Corp DE now owns 752,567 shares of the company’s stock valued at $65,963,000 after purchasing an additional 217,596 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Revvity by 430.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 256,317 shares of the company’s stock worth $22,466,000 after purchasing an additional 208,028 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RVTY. Robert W. Baird raised their target price on shares of Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Barclays lifted their price target on Revvity from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Evercore ISI restated an “outperform” rating on shares of Revvity in a report on Monday, January 5th. Guggenheim began coverage on shares of Revvity in a research report on Wednesday, October 15th. They set a “neutral” rating on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Revvity in a research note on Tuesday, December 9th. They set a “neutral” rating and a $105.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $113.91.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.